Sun Pharma’s Tildrakizumab Study: A Potential Game-Changer for Psoriatic Arthritis

Sun Pharmaceutical Industries Limited ((IN:SUNPHARMA)) announced an update on their ongoing clinical study.

Study Overview: Sun Pharmaceutical Industries Limited is conducting a Phase III clinical study titled ‘Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)’. The study aims to evaluate the efficacy and safety of tildrakizumab, a potential treatment for patients with active psoriatic arthritis who have not previously received anti-TNF therapy. This research is significant as it could offer a new therapeutic option for this patient group.

Intervention/Treatment: The study tests tildrakizumab, an experimental drug administered as a 1 mL injection, against a placebo. The goal is to determine its effectiveness in treating active psoriatic arthritis in patients who are anti-TNF naïve.

Study Design: This interventional study is randomized and follows a parallel assignment model. It is single-masked, meaning the outcomes assessor is unaware of which treatment the participants receive. The primary purpose is treatment-focused, aiming to assess the therapeutic potential of tildrakizumab.

Study Timeline: The study commenced on July 1, 2020, and is currently active but not recruiting. The latest update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence market dynamics.

Market Implications: The ongoing study by Sun Pharmaceutical could significantly impact its stock performance, especially if tildrakizumab proves effective. Success in this trial could enhance Sun Pharma’s market position in the psoriatic arthritis treatment sector, potentially affecting investor sentiment positively. Competitors in the pharmaceutical industry will be closely monitoring these developments.

The study is ongoing, with further details available on the ClinicalTrials portal.